Group | Control | PMX-HP | p values |
---|---|---|---|
Intent-to-treat analysis | |||
Number of patients | 14 | 14 | |
T1 TVD (mm/mm2) | 20.8 (20.0–24.1) | 23.3 (20.9–25.2) | 0.069 |
T1 PVD (mm/mm2) | 19.7 (18.8–23.2) | 22.8 (20.9–24.5) | 0.085 |
T2 TVD | 21.1 (19.9–22.9) | 24.2 (22.1–24.9) | 0.007 |
T2 PVD | 20.0 (18.9–21.6) | 22.9 (20.9–24.9) | 0.008 |
As-treated analysis | |||
Number of patients | 13 | 15 | |
T1TVD | 20.5 (19.9–23.4) | 23.6 (20.9–25.1) | 0.041 |
T1 PVD | 19.3 (18.7–22.5) | 22.9 (20.9–24.4) | 0.037 |
T2 TVD | 20.7 (19.8–22.7) | 23.9 (22.1–24.9) | 0.003 |
T2 PVD | 19.8 (18.8–21.0) | 23.0 (21.3–24.9) | 0.002 |
Per-protocol analysis | |||
Number of patients | 13 | 14 | |
T1TVD | 20.5 (19.9–23.4) | 23.3 (20.9–25.2) | 0.048 |
T1 PVD | 19.3 (18.7–22.5) | 22.8 (20.9–24.5) | 0.048 |
T2 TVD | 20.7 (19.8–22.7) | 24.2 (22.1–24.9) | 0.005 |
T2 PVD | 19.8 (18.8–21.0) | 22.9 (20.9–24.9) | 0.004 |